Can Intellia's lonvo-z Turn CRISPR Promise into HAE Practice? on June 17, 2026 Angioedemas, Hereditary Attack device Blackfoot language CRISPR gene editing HAELO in vivo therapy Intellia kininogenase KLKB1 gene lonvo-z NTLA-2002 Phase 3 trial United States Food and Drug Administration +